INTRODUCTION
Choline and related lipid compounds are vital metabolites to maintain cellular homeostasis and to support proliferation of both normal and tumor cells. It is required for the synthesis of phosphatidylcholine (PC), the major phospholipid in eukaryotic membranes, and other phospholipids which are relevant to maintain cell membrane integrity and signal transduction both in normal conditions and disease including cancer (reviewed in 1-3).
Generation of phosphocholine (PCho) by choline kinase alpha (ChoKα) is an essential event for growth factor signaling. There is data supporting the role of PCho in malignant transformation as RAS-transformed cell lines show increased ChoK activity and higher PCho levels than their normal counterparts (4) . Furthermore, increased activity of ChoKα is observed in a large series of human tumors and tumor-derived cells lines including breast, lung, colorectal, prostate, bladder, ovary, liver and osteosarcomas (5) (6) (7) (8) (9) (10) (11) , and its activity has been found to be a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression (6, 7, 12) . All these evidences as well as NMR studies of choline and related compounds in both normal and tumor cells, have driven to the conclusion that abnormal choline metabolism is a metabolic hallmark associated with tumor onset and progression, and supported further the proposal for using ChoKα as a novel therapeutic target and a biomarker for cancer prognosis and treatment (1) (2) (3) .
Several different molecules were initially used as choline kinase antagonists (1) . A successful series of symmetrical bis-quinolinium compounds based on the hemicolinium-3 (HC-3) molecule have been synthesized as inhibitors of ChoKα with promising activity as antiproliferative compounds against tumor-derived cells and as antitumoral drugs in xenographs models (13) (14) (15) (16) (17) (18) (19) (20) . MN58b, a first generation ChoKα inhibitor, shows a potent in vitro antiproliferative activity and in vivo antitumoral activity (1, 13, 14) . It is highly specific since it demonstrates a differential effect in normal cells versus tumor cells. In primary cells, blocking de novo PCho synthesis by MN58b promotes a reversible cell cycle arrest at G0/G1 phase. By contrast, ChoK inhibition in tumor cells makes cells unable to arrest in G0/G1 as marked by a deficient pRb dephosphorylation (21, 22) . In addition, MN58b has provided strong evidence that it is specific to ChoKα, with no effect in a variety of oncogene-activated signaling pathways (21) (22) (23) . Furthermore MN58b showed a much higher specificity against ChoKα1 (IC 50 =5 μM) than against ChoKβ (IC 50 =107.5 μM), this is 21.5 times more potent against ChoKα1 than ChoKβ isoform (24). All these results have been validated by ChoKα-specific RNA-interfering (siRNA) approaches (7, (25) (26) (27) ) and additional small molecules directed towards ChoKα (28) (29) .
Once the proof of principle that ChoKα is a validated target in oncology has been set up, a very intensive activity has been developed for the identification of novel ChoKα inhibitors with potential use as antitumoral drugs (15) (16) (17) (18) (19) (20) (28) (29) (30) (31) and also as antiparasitic compounds (32, 33) .
In humans, there are two genes codifying for ChoK activity, CHKA and CHKB, and three different enzymes ChoKα1, ChoKα2 and ChoKβ (reviewed in 1,2). While ChoKα1 and ChoKα2 are almost identical and are generated by differential splicing from the CHKA genes, ChoKβ, which shares a 60% of overall homology, is generated from CHKB. Thus, ChoKβ is a different gene product, and although is able to convert choline into PCho in cell extracts, its main role in living cells seems to be the phosphorylation of ethanolamine to phosphoethanolamine (24). Thus, probably due to this differential biochemical behavior, whereas ChoKα has been involved in the tumorigenic process, a similar role for ChoKβ in carcinogenesis has not been found (24). Recent evidence further support the relevance of ChoKα as a bonafide anticancer drug target (34) . This makes necessary the identification of specific ChoKα inhibitors as anticancer drugs.
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Limited therapeutic outcomes of existing drugs, diverse toxic side effects, along with acquired resistance to multiple drugs, are frequent drawbacks of current cancer therapies.
Therefore, there is a clinical need for new and more precise compounds that can specifically inhibit novel selected targets, guaranteeing the continuous improvement in the search for new cancer-targeted drugs, with a higher therapeutic window and less toxicity. Here we report the preclinical development of RSM-932A as the first-in-man ChoKα inhibitor to enter Phase I clinical trials. Compound RSM-932A is a rationally designed targeted agent with a potential for combinatorial treatments in cancer patients due to its novel mechanism of action.
MATERIALS AND METHODS

Cell cultures and compound sensitivity assays
All cell lines used in this study were obtained from the American Type Culture Collection, Rockville, MD, no authentication was done by the authors.. Cells were grown in the recommended growth media by the provider under standard conditions at 37 ºC, 5% CO 2 and 98% humidity. compound at which the remaining cell number is 50% equivalent to that of time 0). Twenty four hours after seeding the cells and before the exposure to the drug, a time zero point was read in order to calculate these parameters.
Synthesis of compounds
Compounds were synthesized as previously described (15) (16) (17) (18) (19) (20) 35) . The structure of all the compounds are shown as derivatives of the general structure depicted in Supplementary 
Effective Dose
The experiments to find the optimal dosis for the in vivo experiment were performed using 4-5 Swiss immunocompetent mice for each dose. Groups of mice were treated with each substance with different concentrations. All compounds were diluted at the same concentration as a stock solution (5 mM) and successive dilutions were done in Phosphate Buffer Saline (PBS, 1X) for injections. The treatment consists in a daily i.p. injection during 5 days, followed by 9 day-rest and a final cycle of 5 day-treatment. During this time, mice were daily observed and any change in behavior, fur, weight or mobility considered. All toxicity data were recorded, specifying the details of death cases during and at the end of the treatment. Survivor mice were sacrificed and all the organs were fixed for histopathological analysis (data not shown). The Effective Dose was defined as the highest concentration that induced no deaths after two 5 day-treatment cycles. This dose was used for further toxicity and antitumoral activity experiments.
Tumor Growth Inhibition Studies
Six-week-old nude mice were used. Mice were s.c. At the end of treatment all animals from each group were sacrificed. All macroscopic abnormalities observed during the dissection were documented. Lungs were perfused with 4%
formaldehyde and the rest of the organs post-fixed in the same fixative for at least 24 hours.
After fixation, representative samples for each organ were obtained and embedded in paraffin.
Sections of 6 µm of thickness of each block of paraffin were cut and stained by the routine haematoxylin-eosin method. The histological material was assessed by an independent experienced pathologist with ample experience in mice pathological analysis (CitoPath S.L.)
under a Leica DM LS2 light microscope. Micrographs were taken with a Leica EC3 camera attached to the microscope. Liver sections from mice in the control group showed normal liver histology and described as (-). Liver sections from mice in the treated group showed either no alteration (-), slight changes referred to some binucleated hepatocytes and some with enlarged nuclei (+). Moderate changes include also cleared cytoplasm with a single vacuole (++), and acute changes showed all previously mentioned characteristic plus a diffuse mottling of the cytoplasm (+++).
For i.p. drug administration, the compounds were dissolved every week of treatment at 5 mM and kept protected from light at 4 ºC, and successive dilutions were done fresh every day of treatment in sterile PBS. For the i.v. route of administration, RSM-932A was dissolved at 50 mM (100% DMSO, Baker) and successive dilutions were done fresh every day of treatment in sterile 5% dextrose water (Viaflo).
Enzymatic Activity Assays
Recombinant bacterial extracts, in which it has been introduced the expression of human The samples were solved by Thin Layer Chromatography (TLC 60A Silica Gel Whatman).
The radioactivity corresponding to phosphocholine was quantified with the Cyclone Plus Scanner. Concentration of each compound that produces 50% inhibition was calculated and expressed in µM (IC 50 ).
Immunohistochemistry
Tumors from xenographs grown in athymic mice were dissected and fixed in 4%
formaldehyde for at least 24 hours and paraffin-embedded and stained by routine H&E Micrographs were taken with a Leica EC3 camera attached to the microscope.
Statistical analysis
Comparisons in tumor volumes between the untreated and treated groups were done using the non-parametric Mann-Whitney test. Two side p-values less than 0.05 were considered statistically significant. All calculations were performed using SPSS software, version 19.0 (SPSS Inc, Chicago, Illinois). 
RESULTS
Inhibition of specific enzymatic activity of ChoKα and antiproliferative effect in human tumor-derived cells
A battery of designed ChoKα inhibitors previously described (35) were tested for their ability to efficiently blocking the conversion of choline into PCho by the human ChoK-driven enzymatic reaction. In order to differentiate between the inhibitory activity against ChoKα and ChoKβ, the two human isoforms of choline kinase were expressed in an E. coli bacterial strain that lacks choline kinase activity, thus the observed enzymatic activity is due exclusively to the recombinant-expressed isoform of the human choline kinase. As shown in Table 1 , all compounds tested are more specific for ChoKα than for ChoKβ by 6-400-fold.
Subsequently we tested the in vitro ability of these compounds to inhibit cell proliferation using the human colon adenocarcinoma HT-29 cell line as model. Table 2 shows that although the sensitivity varies for some compounds, most of them have good antiproliferative IC 50 values maintaining their main features: selective inhibition of the enzymatic activity of ChoKα and potent antiproliferative activity.
Maximum Tolerated Dose in mice of ChoKα inhibitors
HC-3 is a potent inhibitor of the choline transporter with drastic toxic effects on the cholinergic terminals (36) . In the first generation of derivatives, poor tolerated compounds were obtained that however were sufficient to display antitumoral activity. Among them, MN58b shows an efficient antitumoral effect in several systems but has a limited therapeutic window (13, 14) . The maximum tolerated dose was determined for later experiments in athymic mice. To that end, 4-5 mice were tested with increasing concentrations of each compound for 5 consecutive days followed by 9 days rest and a final cycle of a 5 day- treatment. Table 2 shows animal survival at the experimental endpoint for the different concentrations tested. All external signs of toxicity (weight loss, behavioral changes and fur appearance) as well as lethality were recorded and evaluated to choose a safe dose for subsequent experiments whose objective is to find the final active and non-toxic dosage. A safe dose was established for all compounds as shown in Table 2 and used for further experiments as the effective dose.
Tumor growth inhibition by ChoKα inhibitors
Based on these toxicity results, compounds were subjected to growth inhibition studies at the specified effective dose. The human colon cancer HT-29 cell line was chosen for tumor growth inhibition studies due to its relative well differentiated and aggressive phenotype.
Mice bearing HT-29-derived tumors were treated i.p. with a daily dose for five days, followed by nine days rest and a second cycle of five consecutive daily treatments. Under these conditions, all the analyzed compounds displayed significant tumor growth inhibitory activity when compared to the tumor growth of the control mice treated with vehicle with RSM-820C, RSM-964A, RSM-932A and RSM-828B as the most active compounds (Table 2; Fig 1A) .
Next, all drugs were tested following a more restrictive treatment schedule consisting on one single injection per week for 4 weeks. Fig. 1B, 1C shows the differences found between the two compounds with the best activity under the more restrictive conditions (RSM-932A, RSM-820C).
Data of external toxicity was recorded, and at the end of the treatment, all mice were sacrificed and all organs fixed for histopathology analysis. Table 3 illustrates the antitumor efficacy for each drug as well as the toxicity found in liver, although all main organs were analyzed. No significant organ damage was observed apart from hepatotoxicity that was found in all treatments except for the less aggressive treatment with RSM-932A that showed no liver toxicity while retaining a potent antitumoral activity (77%). Table 3 summarizes toxicity effects for all compounds along with their antitumoral activities. The histological changes found in liver in all cases but one (RSM-824B) were only moderately different to normal tissue. Compound ACG-416B was not evaluated due to its low effect on tumor growth inhibition. Based on all these results, RSM-932A was chosen for further preclinical studies because of its performance with both treatment schedules and its low toxicity.
RSM-932A activity in tumor xenographs
The tumor growth inhibition of RSM-932A under different conditions of doses (7. Table 4 .
Two routes of administration were compared, i.p. and i.v. RSM-932A was used at 3 mg/kg on a three days per week schedule during 4 weeks by either route (Fig 1D) , and the inhibition of tumor growth registered along the duration of the experiment, 25 days. (Fig. 1E) .
RSM-932A antiproliferative activity determined by in vitro screening
RSM-932A was tested against a wide panel of 27 human cancer cell lines and a nontumorigenic cell line as a control (Table 5) 
DISCUSSION
Preclinical efficacy studies based on mice xenographs are the main strategy to select compounds that will be eventually analyzed to determine pharmacological safety for further clinical development in humans. The clinical results of agents used in routine cancer therapy demonstrate the importance of the efforts that should be made in preclinical research in order to reduce superfluous human studies and optimize clinical responses. Selective kinase inhibitors are considered a main division of cancer therapeutics. Therefore, development of new tailored kinase inhibitors into drugs is a priority in cancer research.
HC-3 is a known inhibitor of choline kinase (36) . Its target is overexpressed in a variety of tumors that are the main cause of death worldwide (5-11). However its extremely high toxicity makes it impossible to use it as a pharmacological anticancer drug (1, 36) . The development of HC-3 derivatives as a strategy to develop a potential novel anticancer treatment based on the inhibition of ChoK activity has been a successful strategy initiated in our group (1). Modifications on its structure have been introduced to eliminate the unwanted effects of HC-3 on cholinergic terminals and therefore reduce its high toxicity (13) (14) (15) (16) (17) (18) (19) (20) .
MN58b was selected as the lead compound to further explore its suitability as anticancer drug (13, 14) and to unravel the mechanism of action and consequences of inhibitors of the ChoK enzymatic activity (21-23,37). Thus, MN58b belongs to a first generation of HC-3 derivatives used as a prototype for the selective inhibition of ChoKα to study its effects in both normal 
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